It doesn’t matter how well a drug kills cancer cells if the patient doesn’t stay on treatment. Side effects lead many patients to interrupt dosing of a drug regimen, allowing cancer to advance, said ...
SAN FRANCISCO--(BUSINESS WIRE)--Kivu Bioscience, a biotech company developing next-generation antibody-drug conjugates to deliver best-in-class therapeutics, announced today the close of a $92 million ...
Funding to support clinical development of multiple antibody-drug conjugate (ADC) programs Utilizing the Synaffix platform designed to minimize off-target toxicity and improve efficacy World-class ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback